Exabis Library
Welcome to the e-CCO Library!
P394: Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P395: Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P395: Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P395: Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P395: Real-life prospective experience with adalimumab in ulcerative colitis in Italy: preliminary results of a pilot study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P395: Short-term clinical efficacy and safety of teduglutide for Crohn's disease patients with short bowel syndrome
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P396: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P396: COVID-19 pandemic-related endoscopy delays did not translate to deleterious outcomes for patients with Inflammatory Bowel Disease: A retrospective cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P396: Cyclosporin A efficacy in a paediatric ulcerative colitis: a retrospective single-centre study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P396: Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P396: Monitoring adalimumab compliance using smart sharp bin technology
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P396: Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P396: Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P397 Surveillance in ulcerative colitis: Can we predict the risk for intraepithelial neoplasia?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P397: Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P397: Approach and management of psychological aspects of inflammatory bowel disease described by patients and physicians in Spain. The ENMENTE Project
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM